| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| EXCALIBER-RRMM | 21-10 | relapsed or refractory multiple myeloma |
This study is to compare Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma |
DSSG Group: Lymphoma & blood cancers
DREAMM-14
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| DREAMM-14 | 21-47 | The target population for this study are patients with relapsed refractory multiple myeloma |
This study is a phase 2, randomized, parallel, open-label study to investigate the safety, efficacy, and pharmacokinetics of various dosing regimens of single-agent Belantamab Mafodotin (GSK2857916) in participants with relapsed or refractory multiple myeloma |
TAK-573-1501
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| TAK-573-1501 | 22-14 | The target population for this study are patients with relapsed refractory multiple myeloma |
This study is a phase 1/2, open-label study to investigate the safety and tolerability, efficacy, pharmacokinetics, and immunogenicity of Modakafusp Alfa (TAK-573) as a single agent in patients with relapsed refractory multiple myeloma |
AFFIRM-AL
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| AFFIRM-AL | 22-13 | The target population for this study are Mayo Stage IV AL amyloid patients |
This study is a Phase III, global, randomised double-blind trial of birtamimab plus standard of care vs placebo plus standard of care in Mayo Stage IV AL amyloid patients |
Isa-RVD
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Isa-RVD | 19-34 | The target population for this study are patients with newly diagnosed multiple myeloma for high dose therapy and autologous stem cell transplant. Patients will have a confirmed diagnosis of multiple myeloma, based on standard IMWG criteria. |
This study is a Phase II, multi-centre, single-arm, open-label study to evaluate the efficacy and safety of the combination regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in patients with newly diagnosed multiple myeloma |
CPD-DARA
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| CPD-DARA | 19-17 | The target population for this study are patients with relapsed/refractory multiple myeloma (MM). Patients will have a confirmed diagnosis of MM, with measurable disease as per IMWG criteria, in the second relapse and beyond (third line of therapy and beyond) |
This study is a Phase Ib, open label, single arm, adaptive multi-centre clinical study of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in patients with relapsed/refractory multiple myeloma |
MOR208C310
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MOR208C310 | 20-35 | Newly-diagnosed diffuse large B-cell lymphoma (DLBCL). |
This Study is comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL). |
INDEPENDENCE ACE-536-MF-002
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| INDEPENDENCE ACE-536-MF-002 | 20-34 | Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions |
This Study is to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions. |
HOVON 156
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| HOVON 156 | 19-16 | Newly diagnosed diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with FLT3 mutations eligible for intensive chemotherapy |
This trial will compare Gilteritinib and midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy |
HOVON 150
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| HOVON 150 | 19-18 | Newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy |
This trial will compare ivosidenib and enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy |